A controlled study of penfluridol in the treatment of chronic schizophrenia.
Twenty patients were treated with penfluridol and 21 with fluphenazine for a period of up to 1 year. Penfluridol, an oral neuroleptic administered weekly was as efficacious as fluphenazine administered twice daily and appeared to be superior to fluphenazine in improving emotional withdrawal and anergia. The low incidence of side effects and other signs of toxicity, coupled with an effective prophylactic activity, suggests that penfluridol is an important addition to our therapeutic armamentarium for the treatment of chronic schizophrenia.
D000328:Adult; D000553:Ambulatory Care; D002908:Chronic Disease; D005260:Female; D005476:Fluphenazine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010395:Penfluridol / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D010880:Piperidines; D010395:Penfluridol; D005476:Fluphenazine